The London-listed pharmaceuticals group Shire has bolstered its rare disease drug pipeline with the acquisition of the US biopharmaceutical company Lumena Pharmaceuticals. As well as its late stage rare disease…
Shire boosts rare disease portfolio with Lumena buy
Would you like to read this article?
Register below to continue reading this article.
You will be able to read 2 articles. No payment details required.
You will also receive our daily M&A insights email.
There is no obligation to subscribe to the service but we hope that after the trialing your firm will decide to subscribe.
For details of subscription packages or if you are considering a subscription and would like to read a few more articles on your trial, please contact us at subscriptions@acquisitionsdaily.com and we will call you to discuss.
Already a subscriber? Login here
